BeOne Medicines Ltd. (NASDAQ:ONC) Q2 2025 Earnings Call Transcript
Daniel Maller: Hello and welcome. Thanks for joining us today. I'm Dan Miller, Head of Investor Relations at BeOne Medicines.
Beone Medicines Ltd. (ONC)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 8,799,053 | $2,129,986,760 | 20.66% | |
| 2. | Hillhouse Capital Management Lei Zhang | 1,034,306 | $250,374,453 | 8.06% | |
| 3. | Citadel Investment Group Ken Griffin | 537,156 | $130,029,353 | -46% | 0.02% |
| 4. | Siren L.L.C. Raymond Debbane | 509,990 | $123,453,279 | +3% | 6.39% |
| 5. | Marshall Wace LLP Paul Marshall And Ian Wace | 467,590 | $113,189,509 | -3% | 0.13% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $302.06 | 165,529 | $49,999,938.03 | 18,943,802 | 2021-09-10 | Filing | |
| $108.00 | 5,231,900 | $565,045,200.00 | 5,250,491 | 2018-08-02 | Filing | |
| $108.00 | 582,200 | $62,877,600.00 | 600,791 | 2018-08-02 | Filing | |
| $101.00 | 1,645,148 | $166,159,948.00 | 5,121,404 | 2018-01-18 | Filing | |
| $101.00 | 335,050 | $33,840,050.00 | 708,025 | 2018-01-18 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $308.03 | 600 | $184,819.32 | 0 | 2025-08-14 | Filing | |
| $307.43 | 4,917 | $1,511,625.93 | 600 | 2025-08-14 | Filing | |
| $306.26 | 12,232 | $3,746,189.44 | 5,517 | 2025-08-14 | Filing | |
| $305.48 | 8,522 | $2,603,297.15 | 17,749 | 2025-08-14 | Filing | |
| $304.19 | 500 | $152,097.45 | 26,271 | 2025-08-14 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 5,088,279 | $1,231,719,699 | 0.98% | |
| 2. | 4,885,006 | $1,182,242,053 | 0.2% | |
| 3. | 3,449,793 | $835,091,374 | 0.05% | |
| 4. | 1,010,465 | $244,603,263 | 0.94% | |
| 5. | 501,189 | $121,322,716 | 0% |
News See All
BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra
BeOne Medicines Ltd. (NASDAQ:ONC), formerly BeiGene, is a global oncology company now headquartered in Switzerland following its May 2025 redomiciliation.
10 Most Undervalued Healthcare Stocks to Buy According to Analysts
The CEO of Pivotal Advisors, Tiffany McGhee, spoke on CNBC on June 27 on what investors should do in light of the current state of the market.
BeOne Medicines Ltd. (ONC)’s Combo Drug Shows Strong CLL Response
BeOne Medicines Ltd.
Billionaire Lei Zhang's 10 Stock Picks with Huge Upside Potential
Lei Zhang, the founder and CEO of Hillhouse Capital, is one of the most influential yet low-profile figures in the world of investing.
BeiGene, Ltd. (NASDAQ:ONC) Q1 2025 Earnings Call Transcript
Dan Maller: [Abrupt Start]…our Investor Relations website, along with our earnings release.
Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025
No matter the market environment, you’ll always find entertainment in the biotech space.
10 Best Immunology Stocks To Buy Now
Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies.
BeiGene, Ltd. (NASDAQ:ONC) Q4 2024 Earnings Call Transcript
Operator: Good day, everyone. Welcome to BeiGene's Q4 and Full Year 2024 Earnings Call Webcast. All lines have been placed on mute to prevent any background noise.
BeiGene, Ltd. (NASDAQ:ONC) Q4 2024 Earnings Call Transcript
Operator: Good day, everyone. Welcome to BeiGene's Q4 and Full Year 2024 Earnings Call Webcast. All lines have been placed on mute to prevent any background noise.
Billionaire Hedge Funds
